Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin

What Was Tested

The paper reports a study of Adrenomedullin, published as an observational study.

Previous studies of MR-proADM have primarily focussed on bacterial infections.

A limited number of small and monocentric studies have examined MR-proADM as a prognostic factor in patients infected with SARS-CoV-2, however there is need for multicenter validation.

Who Took Part

The study group was 1861 patients.

An observational retrospective analysis of 1861 patients, with SARS-CoV-2 confirmed by RT-qPCR, from 10 hospitals across Europe was performed.

Biomarkers, taken upon presentation to Emergency Departments (ED), clinical scores, patient demographics and outcomes were collected.

How the Study Was Run

The researchers set it up as a multicenter study.

More than one site took part, so the patients came from several places.

Multiclass random forest classifier models were generated as well as calculation of area under the curve analysis.

What Was Measured

An evaluation of its utility in predicting need for hospitalisation in viral infections was also performed.

Topics PubMed links to this paper include Adrenomedullin, Biomarkers, C-Reactive Protein, COVID-19, Hospital Mortality, Hospitalization and Prognosis.

The authors tagged it with the keywords Emergency department, Hospital admission, MR-proADM and SARS-CoV-2.

What This Means in Plain Language

The paper is a multicenter study of Adrenomedullin in 1861 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Respiratory research), a journal based in England.

More context: the Adrenomedullin compound page, all human trials.